Glenmark (GLENMARK) | Financial Analysis & Statements
Glenmark Pharmaceuticals Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
30.6B
Gross Profit
20.4B
66.80%
Operating Income
4.5B
14.73%
Net Income
469.7M
1.54%
EPS (Diluted)
₹1.66
Balance Sheet Metrics
Total Assets
160.5B
Total Liabilities
72.0B
Shareholders Equity
88.5B
Debt to Equity
0.81
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Glenmark Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 131.5B | 116.4B | 114.3B | 121.7B | 108.1B |
| Cost of Goods Sold | 47.6B | 48.8B | 45.9B | 47.8B | 40.0B |
| Gross Profit | 83.9B | 67.6B | 68.5B | 74.0B | 68.1B |
| Gross Margin % | 63.8% | 58.1% | 59.9% | 60.8% | 63.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 16.0B | 13.6B | 14.3B | 13.0B | 12.6B |
| Other Operating Expenses | 14.1B | 13.1B | 11.6B | 12.6B | 10.3B |
| Total Operating Expenses | 30.1B | 26.7B | 25.9B | 25.6B | 22.9B |
| Operating Income | 18.7B | 6.3B | 10.8B | 18.4B | 17.2B |
| Operating Margin % | 14.2% | 5.4% | 9.4% | 15.1% | 15.9% |
| Non-Operating Items | |||||
| Interest Income | 439.4M | 61.8M | 70.0M | 94.4M | 26.5M |
| Interest Expense | 2.1B | 5.2B | 3.5B | 3.0B | 3.5B |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 14.0B | 365.0M | 2.4B | 14.4B | 13.8B |
| Income Tax | 3.5B | 18.7B | 3.3B | 4.5B | 4.1B |
| Effective Tax Rate % | 25.2% | 5,116.7% | 137.3% | 31.1% | 29.8% |
| Net Income | 10.5B | -14.3B | 3.8B | 9.9B | 9.7B |
| Net Margin % | 8.0% | -12.3% | 3.3% | 8.2% | 9.0% |
| Key Metrics | |||||
| EBITDA | 24.7B | 21.0B | 19.7B | 24.9B | 21.3B |
| EPS (Basic) | ₹37.11 | ₹-53.22 | ₹10.53 | ₹33.37 | ₹34.38 |
| EPS (Diluted) | ₹37.11 | ₹-53.22 | ₹10.53 | ₹33.37 | ₹34.38 |
| Basic Shares Outstanding | 282188156 | 282170724 | 282168156 | 282168156 | 282168156 |
| Diluted Shares Outstanding | 282188156 | 282170724 | 282168156 | 282168156 | 282168156 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Glenmark Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 16.8B | 16.6B | 11.6B | 14.1B | 11.4B |
| Short-term Investments | 157.6M | 121.3M | 140.9M | 328.8M | 764.0M |
| Accounts Receivable | 33.4B | 18.6B | 36.7B | 31.0B | 25.7B |
| Inventory | 30.3B | 25.1B | 23.7B | 25.0B | 22.8B |
| Other Current Assets | 11.6B | 12.2B | 11.5B | 2.8B | 3.6B |
| Total Current Assets | 93.0B | 74.3B | 107.3B | 82.8B | 73.6B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 33.2B | 31.2B | 39.0B | 2.5B | 2.7B |
| Goodwill | 15.3B | 14.0B | 24.9B | 23.5B | 23.9B |
| Intangible Assets | 13.9B | 12.7B | 23.4B | 22.3B | 22.8B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.8B | 1.5B | 1.5B | -16.0B | 17.0B |
| Total Non-Current Assets | 67.5B | 69.3B | 86.5B | 88.0B | 82.4B |
| Total Assets | 160.5B | 143.6B | 193.7B | 170.8B | 156.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 25.8B | 25.4B | 20.0B | 22.9B | 22.4B |
| Short-term Debt | 17.7B | 10.8B | 5.8B | 11.9B | 8.7B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 100.4M | 877.2M | 58.7M | 122.2M | 286.4M |
| Total Current Liabilities | 59.7B | 58.2B | 51.1B | 46.9B | 42.0B |
| Non-Current Liabilities | |||||
| Long-term Debt | 7.0B | 1.5B | 40.3B | 27.7B | 41.1B |
| Deferred Tax Liabilities | 585.9M | 2.8M | 5.1M | 315.0M | 287.5M |
| Other Non-Current Liabilities | - | 16.9M | 13.3M | 9.2M | 600.7M |
| Total Non-Current Liabilities | 12.3B | 6.9B | 44.3B | 29.6B | 43.4B |
| Total Liabilities | 72.0B | 65.1B | 95.3B | 76.5B | 85.4B |
| Equity | |||||
| Common Stock | 282.2M | 282.2M | 282.2M | 282.2M | 282.2M |
| Retained Earnings | 88.0B | 78.7B | 94.6B | 92.1B | 72.3B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 88.5B | 78.5B | 98.4B | 94.4B | 70.6B |
| Key Metrics | |||||
| Total Debt | 24.7B | 12.3B | 46.1B | 39.6B | 49.9B |
| Working Capital | 33.3B | 16.1B | 56.2B | 35.9B | 31.6B |
Balance Sheet Composition
Glenmark Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 14.0B | 5.7B | 8.7B | 14.4B | 13.8B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | -91.7M | 49.6M | 67.7M | 79.2M | 79.4M |
| Working Capital Changes | -17.1B | -625.4M | -12.4B | -6.5B | -5.5B |
| Operating Cash Flow | 2.1B | 19.1B | 7.3B | 12.7B | 11.5B |
| Investing Activities | |||||
| Capital Expenditures | -7.5B | -9.0B | -5.5B | -7.9B | -6.8B |
| Acquisitions | 7.5B | 54.5B | 0 | - | - |
| Investment Purchases | -117.5M | 0 | -60.1M | -400.2M | 0 |
| Investment Sales | 24.5M | 70.5M | 50.0M | 300.0M | 0 |
| Investing Cash Flow | -400.3M | 45.4B | -5.5B | -3.4B | -6.8B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -704.4M | -1.2B | -1.4B | -927.0M | -704.5M |
| Debt Issuance | 5.1B | 0 | 11.6B | 21.3B | 16.4B |
| Debt Repayment | -1.4B | -36.5B | -5.1B | -30.2B | -17.1B |
| Financing Cash Flow | 11.3B | -32.8B | 3.4B | -1.7B | -514.8M |
| Free Cash Flow | -15.8B | -11.6B | 176.3M | 3.2B | 3.6B |
| Net Change in Cash | 13.0B | 31.7B | 5.2B | 7.6B | 4.2B |
Cash Flow Trend
Glenmark Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
59.35
Forward P/E
27.98
Price to Book
6.60
Price to Sales
3.83
PEG Ratio
3.73
Profitability Ratios
Profit Margin
6.45%
Operating Margin
18.34%
Return on Equity
11.83%
Return on Assets
6.52%
Financial Health
Current Ratio
1.65
Debt to Equity
12.78
Beta
0.29
Per Share Data
EPS (TTM)
₹37.74
Book Value per Share
₹339.57
Revenue per Share
₹585.09
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GLENMARK | 662.6B | 59.35 | 6.60 | 11.83% | 6.45% | 12.78 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Dr. Reddy's | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.





